Solid Biosciences (SLDB) Cash & Current Investments (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Cash & Current Investments for 8 consecutive years, with $171.1 million as the latest value for Q3 2024.
- Quarterly Cash & Current Investments rose 19.76% to $171.1 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $171.1 million through Sep 2024, up 19.76% year-over-year, with the annual reading at $123.6 million for FY2023, 42.15% down from the prior year.
- Cash & Current Investments hit $171.1 million in Q3 2024 for Solid Biosciences, down from $190.3 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $268.5 million in Q1 2021 to a low of $24.8 million in Q3 2020.
- Historically, Cash & Current Investments has averaged $149.0 million across 5 years, with a median of $160.2 million in 2023.
- Biggest five-year swings in Cash & Current Investments: plummeted 76.6% in 2020 and later skyrocketed 398.01% in 2021.
- Year by year, Cash & Current Investments stood at $155.1 million in 2020, then soared by 33.99% to $207.8 million in 2021, then rose by 2.86% to $213.7 million in 2022, then plummeted by 42.15% to $123.6 million in 2023, then soared by 38.4% to $171.1 million in 2024.
- Business Quant data shows Cash & Current Investments for SLDB at $171.1 million in Q3 2024, $190.3 million in Q2 2024, and $206.1 million in Q1 2024.